TMD.TO Titan Medical Inc. TSX C$1.12 pre-market 04 Feb 2026: high volume signals interest

The TMD.TO stock price is trading at C$1.12 in pre-market activity on 04 Feb 2026 after an intraday swing that pushed the share price from C$0.05 to C$1.125. Volume is elevated at 117,220 shares versus a 50-day average of 45,936, marking a 2.55x relative volume. The move follows no public earnings release today, so trading appears driven by repositioning and low float dynamics in this TSX-listed medical devices developer.

Pre-market move: TMD.TO stock trading details

TMD.TO stock is quoted at C$1.12 pre-market with a reported intraday high of C$1.125 and an open of C$0.05. The recorded intraday change equals 2,150.00%, reflecting a low prior close and thin prior liquidity. Market cap stands at C$128,295,000 and shares outstanding are 114,040,000.

Volume and liquidity: what the numbers show

Volume has risen to 117,220 versus an average volume of 45,936, a relative volume of 2.55. Higher trade size on a small-float name can amplify moves and widen spreads, so execution risk is elevated for active traders. Watch bid-ask depth before entering positions.

Fundamentals and valuation for Titan Medical Inc. (TMD.TO stock)

Titan Medical Inc. operates in Healthcare, Medical – Devices and reports EPS of -1.73. The company shows a current ratio of 2.78 and debt to equity of 0.28, indicating balance-sheet liquidity. Market-based ratios are distorted by the recent spike; book-value and price multiples should be treated cautiously during the volume event.

Technical outlook and price targets for TMD.TO stock

Technically, the rapid move leaves a large intraday range between C$0.045 and C$1.125, creating a pocket of potential resistance around the year high C$1.25. Short-term price targets for active traders: a conservative pullback target near C$0.50 and a breakout target near C$1.50 if volume sustains above 100,000 shares.

Meyka AI rating and forecast for TMD.TO stock

Meyka AI rates TMD.TO with a score out of 100: 64.67 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects C$0.45 for TMD.TO stock versus the current price C$1.125, implying -60.00%; forecasts are model-based projections and not guarantees.

Risks and short-term opportunities for TMD.TO stock

Key risks include thin liquidity, volatile spreads, and negative historical EPS of -1.73. Opportunities for traders include momentum scalp trades on sustained volume and longer-term exposure if Enos system milestones progress. Monitor official filings and company updates on the Titan Medical website source.

Final Thoughts

TMD.TO stock shows high pre-market volume and a wide intraday price swing to C$1.12 on 04 Feb 2026, driven by low float and repositioning rather than a new earnings release. The healthcare sector backdrop is mixed, and Titan Medical’s fundamentals include a current ratio of 2.78 and EPS -1.73, which suggest balance-sheet resilience but operating losses. Meyka AI rates TMD.TO with a 64.67 score (B, HOLD) and its model projects C$0.45, implying a -60.00% move from the current reference price C$1.125; forecasts are model-based projections and not guarantees. Traders should treat this as a high-volatility event: intraday momentum strategies may work for experienced traders with strict risk controls, while longer-term investors should wait for clearer clinical or commercial catalysts and confirmatory filings. For live trade context and historical comparables see Medtronic market data source and Titan Medical investor pages on our platform: https://meyka.ai/stocks/TMD.TO. Meyka AI-powered market analysis platform provides updated signals as the day progresses.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.